Combination therapy with probucol prevents adriamycin-induced cardiomyopathy - PubMed

Review

Combination therapy with probucol prevents adriamycin-induced cardiomyopathy

P K Singal et al. J Mol Cell Cardiol. 1995 Apr.

Abstract

Adriamycin (doxorubicin) is a broad spectrum anti-tumor antibiotic used to treat cancer patients. However, the potential usefulness of this drug is currently limited by the development of a dose-dependent cardiomyopathic process terminating in severe heart failure. Although several mechanisms have been suggested to explain the pathogenesis of adriamycin-induced cardiomyopathy, free-radical induced oxidative stress appears to play an important role. A concise description of adriamycin-induced cardiomyopathy is provided. Various combination therapies which have been attempted in the past to modulate the adriamycin-induced cardiomyopathy are also discussed. Recently, it has been discovered that probucol, a lipid lowering agent and potent antioxidant, provides complete protection against adriamycin-induced cardiomyopathy in rats without interfering with the anti-tumor properties of this antibiotic. Clinical trials employing adriamycin therapy in combination with probucol are needed to determine the applied value of these laboratory findings.

Similar articles

• Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.

  Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Siveski-Iliskovic N, et al. Circulation. 1995 Jan 1;91(1):10-5. doi: 10.1161/01.cir.91.1.10. Circulation. 1995. PMID: 7805190

• Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

  Iliskovic N, Singal PK. Iliskovic N, et al. Am J Pathol. 1997 Feb;150(2):727-34. Am J Pathol. 1997. PMID: 9033285 Free PMC article.

• Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant.

  Morishima I, Okumura K, Matsui H, Kaneko S, Numaguchi Y, Kawakami K, Mokuno S, Hayakawa M, Toki Y, Ito T, Hayakawa T. Morishima I, et al. J Pineal Res. 1999 May;26(4):204-10. doi: 10.1111/j.1600-079x.1999.tb00585.x. J Pineal Res. 1999. PMID: 10340722

• Adriamycin cardiomyopathy: pathophysiology and prevention.

  Singal PK, Iliskovic N, Li T, Kumar D. Singal PK, et al. FASEB J. 1997 Oct;11(12):931-6. doi: 10.1096/fasebj.11.12.9337145. FASEB J. 1997. PMID: 9337145 Review.

• Adriamycin-induced heart failure: mechanism and modulation.

  Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. Singal PK, et al. Mol Cell Biochem. 2000 Apr;207(1-2):77-86. doi: 10.1023/a:1007094214460. Mol Cell Biochem. 2000. PMID: 10888230 Review.

Cited by

• Role of bone marrow mesenchymal stem cell-derived exosomes in reducing neurotoxicity and depression-like behaviors induced by doxorubicin in rats.

  Abdel-Gawad DRI, Khalil F, Shehata O, Ibrahim MA, El-Samannoudy S, Mahdi EA, Shaban NS. Abdel-Gawad DRI, et al. Toxicol Res (Camb). 2024 Oct 3;13(5):tfae159. doi: 10.1093/toxres/tfae159. eCollection 2024 Oct. Toxicol Res (Camb). 2024. PMID: 39371677

• Anthracycline-induced cardiomyopathy.

  Fisher NG, Marshall AJ. Fisher NG, et al. Postgrad Med J. 1999 May;75(883):265-8. doi: 10.1136/pgmj.75.883.265. Postgrad Med J. 1999. PMID: 10533628 Free PMC article.

• Cardioprotective interventions for cancer patients receiving anthracyclines.

  van Dalen EC, Caron HN, Dickinson HO, Kremer LC. van Dalen EC, et al. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD003917. doi: 10.1002/14651858.CD003917.pub4. Cochrane Database Syst Rev. 2011. PMID: 21678342 Free PMC article. Review.

• Doxorubicin induced heart failure: Phenotype and molecular mechanisms.

  Mitry MA, Edwards JG. Mitry MA, et al. Int J Cardiol Heart Vasc. 2016 Mar;10:17-24. doi: 10.1016/j.ijcha.2015.11.004. Int J Cardiol Heart Vasc. 2016. PMID: 27213178 Free PMC article.

• Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.

  Lódi M, Priksz D, Fülöp GÁ, Bódi B, Gyöngyösi A, Nagy L, Kovács Á, Kertész AB, Kocsis J, Édes I, Csanádi Z, Czuriga I, Kisvárday Z, Juhász B, Lekli I, Bai P, Tóth A, Papp Z, Czuriga D. Lódi M, et al. J Transl Med. 2019 Jul 19;17(1):229. doi: 10.1186/s12967-019-1978-0. J Transl Med. 2019. PMID: 31324258 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal